Fagron

Fagron publishes its annual report 2024

06 Mar 2025 01:00:00 By Nasdaq GlobeNewswire

Fagron delivers exceptional performance with 14% topline growth and 17% increase in REBITDA for FY 2024

20 Feb 2025 01:00:00 By Nasdaq GlobeNewswire

Fagron solidifies its leadership position with the acquisition of Guinama in Spain

04 Feb 2025 01:00:00 By Nasdaq GlobeNewswire

Fagron strengthens its market positioning with the acquisitions of CareFirst in North America and Injeplast in Brazil

07 Jan 2025 01:00:00 By Nasdaq GlobeNewswire

Fagron updates on FDA communication regarding the June 2024 inspection at Wichita

23 Dec 2024 01:00:00 By Nasdaq GlobeNewswire

Disclosure of notification received from FMR LLC

26 Nov 2024 12:59:27 By Nasdaq GlobeNewswire

Fagron reports outstanding third quarter 2024 performance with 12.1% revenue growth and reaffirms full-year outlook

10 Oct 2024 01:00:00 By Nasdaq GlobeNewswire

Disclosure of notification received from AOC Pharma S.à r.l.

08 Oct 2024 16:00:00 By Nasdaq GlobeNewswire

Fagron completes share buy-back program

13 Sep 2024 12:28:48 By Nasdaq GlobeNewswire

Fagron’s share buy-back program: Weekly update

06 Sep 2024 12:24:46 By Nasdaq GlobeNewswire

Fagron’s share buy-back program: Weekly update

30 Aug 2024 12:34:33 By Nasdaq GlobeNewswire

Fagron’s share buy-back program: Weekly update

23 Aug 2024 12:44:55 By Nasdaq GlobeNewswire

Fagron delivers strong performance with 16% topline growth and 17% increase in REBITDA for the first half of 2024

01 Aug 2024 01:00:00 By Nasdaq GlobeNewswire

Fagron shareholders approve all voting items at AGM and EGM

13 May 2024 13:00:00 By Nasdaq GlobeNewswire

Fagron publishes agenda for 2024 annual shareholders meeting and extraordinary general meeting

12 Apr 2024 02:00:00 By Nasdaq GlobeNewswire

Record revenue of €209 million in first quarter reflecting 15% topline growth

11 Apr 2024 01:00:00 By Nasdaq GlobeNewswire

Disclosure notification from Mawer Investment Management Ltd.

19 Mar 2024 13:00:00 By Nasdaq GlobeNewswire

Fagron publishes annual report 2023

14 Mar 2024 13:30:00 By Nasdaq GlobeNewswire

Fagron delivers strong performance with 12% topline growth and 14% increase in REBITDA for FY 2023

15 Feb 2024 01:00:00 By Nasdaq GlobeNewswire

Disclosure notification from AOC Pharma S.à r.l. – passing 10% threshold

08 Jan 2024 02:00:00 By Nasdaq GlobeNewswire